NIHR Birmingham Biomedical Research Centre

Selinexor potentiates NK cell activation against multiple myeloma

INTRODUCTION: Selinexor is a first in class selective inhibitor of nuclear export (SINE) targeting Exportin-1 (XPO1) and approved for the treatment of multiple myeloma (MM). Selinexor has previously been shown to enhance natural killer (NK) cell activation against lymphoma cells...

ROS/HIF-1 signalling in alveolar macrophages: implications for lung fibrosis

Alveolar macrophages (AMs) in idiopathic pulmonary fibrosis (IPF) display stabilisation of hypoxia inducible factor (HIF)-1 despite their residence within the well oxygenated alveolar space. This highlights a contradiction between oxygen supply and hypoxic signalling in the fibr...

Optical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension

Abstract Background Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could...

Understanding the impact of Multiple Long-Term Conditions (MLTC) on the completion of delirium screening documentation: analysis using routinely collected clinical data

Abstract Introduction Multiple Long-Term Conditions (MLTC) are a recognised risk factor for delirium, but little is known about the impact of MLTC on delirium screening. This study aimed to explore the impact of MLTC on delirium screening documentation for older, hospitalised peo...

Management of Acute Periodontal Conditions—The EFP S2k Level Clinical Practice Guideline

BACKGROUND: The European Federation of Periodontology (EFP) has developed Clinical Practice Guidelines (CPGs) for the treatment of periodontitis and for the management of peri-implant diseases. In accordance with the 2018 Classification, acute periodontal conditions are character...

Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe KIDNEY involvement

Abstract Introduction The RAVE/RITUXIVAS trials established rituximab (RTX) therapy in ANCA-associated vasculitis (AAV). However, RAVE excluded patients with severe renal involvement (creatinine > 354 µmol/L). Whilst RITUXIVAS did not, treatment included RTX with 2 cyclophosphami...

Oral health and systemic health outcomes: A call for interdisciplinary action

Abstract Objectives To make the case, from periodontology and dental public health, for interdisciplinary action on oral and systemic health, and to set out recommendations for practice, policy, education, and research. Materials and Methods A joint working group of the European...

22 Quality of life and services use in patients diagnosed with brain tumours: data from a national cancer survivorship study

Abstract Introduction About 13,000 new patients are diagnosed annually with a primary brain tumour in the UK and less than 20% of patients survive 10 years post-diagnosis. Patient-Reported Outcomes and Experiences (PROMs & PREMs) are largely used in clinical trials that recruit f...

Approaches to sharing trial results with adult patients and the public: a qualitative interview and focus group study

<title>Abstract</title> Background Sharing trial results with participants is increasingly recognised as an ethical obligation that fosters trust, respect, and engagement. Yet in practice, results are rarely shared. Researchers often lack guidance on what information to include o...